Glomerulonephritis, Membranous clinical trials
The registry lists 144 studies for Glomerulonephritis, Membranous across more than 10 countries. 58 are recruiting or about to start. 110 of them are mainly about Glomerulonephritis, Membranous (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-10.
Get an email when these change. Save the Glomerulonephritis, Membranous studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Status
Who runs them
Qianfoshan Hospital (8) · Centre Hospitalier Universitaire de Nice (7) · Mario Negri Institute for Pharmacological Research (6) · Mayo Clinic (5) · Radboud University Medical Center (4) · Beijing Friendship Hospital (4) · Istanbul University (3) · University of Michigan (3)
What is being tested here
Drugs under test in Glomerulonephritis, Membranous studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Rituximab | 5 | 8 | 13 |
| Cyclosporine | 2 | 3 | 5 |
| Prednisone | 2 | 2 | 4 |
| Cyclophosphamide | 2 | 2 | 3 |
| Belimumab | 1 | 0 | 3 |
| Obinutuzumab | 1 | 0 | 2 |
| IM19 | 1 | 0 | 1 |
| N-acetylmannosamine | 1 | 0 | 1 |
| Inebilizumab | 1 | 1 | 1 |
| Rivaroxaban | 1 | 0 | 1 |
Drug classes tested here Calcineurin inhibitors 2 open · Factor Xa inhibitors 1 open
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
The 10 nearest, phase 3 first
- Dec 2026A Clinical Study of B007 in the Treatment of Primary Membranous Nephropathy. · Phase 3 · Shanghai Jiaolian Drug Research and Development Co., Ltd
- Oct 2027A Study to Examine the Efficacy and Safety of Zanubrutinib Given to Adults With Primary Membranous Nephropathy · Phase 3 · BeOne Medicines
- Nov 2026Autoreactive B Cells in Membranous Nephropathy · Mario Negri Institute for Pharmacological Research
- Dec 2026Study of YK012 in Primary Membranous Nephropathy · Excyte Biopharma Ltd
- Dec 2026A Phase I Clinical Study of Recombinant Humanized Anti-CD20(B-lymphocyte Antigen CD20) Monoclonal Antibody Subcutaneous Injection in the Treatment of Primary Membranous Nephropathy · Shanghai Jiaolian Drug Research and Development Co., Ltd
- Dec 2026Correlation and Clinical Utility of Urinary Biomarker in Membranous Glomerulonephritis · Chinese University of Hong Kong
- Dec 2026Rivaroxaban in Idiopathic Membranous Nephropathy · Beijing Friendship Hospital
- Jan 2027A Study to Evaluate the Efficacy, Safety, and Tolerability of Human Sialidase Fusion Protein (HLX79) in Combination With Rituximab Injection Versus Placebo in Patients With Active Glomerulonephritis · Shanghai Henlius Biotech
- Mar 2027A Phase II Study of Zuberitamab Injection in Patients With Primary Membranous Nephropathy · BioRay Pharmaceutical Co., Ltd.
- Apr 2027A Study to Learn More About the Effects and Safety of JMT601 in Adults With Primary Membranous Nephropathy · Shanghai JMT-Bio Inc.
Who these studies take
Of the 40 Glomerulonephritis, Membranous studies recruiting now, 14 (35%) set no upper age limit and 13 (33%) stop at 75 or younger. 7 (18%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 2 (5%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 7 (18%) | 7 (18%) |
| 18 | 40 (100%) | 40 (100%) |
| 30 | 40 (100%) | 40 (100%) |
| 40 | 40 (100%) | 40 (100%) |
| 50 | 40 (100%) | 40 (100%) |
| 65 | 40 (100%) | 40 (100%) |
| 75 | 39 (98%) | 39 (98%) |
| 85 | 18 (45%) | 18 (45%) |
Across all 144 studies, recruiting or not: 36% stop at 75 or younger and 6% at 65; 12% take children; 1% are for women only and 0% for men only; 8% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
What changed recently
From the registry's own updates since Oct 13, 2026.
Newly registered1
- MENA/Levant Epidemiological, Registry of Immunological & Clinical Traits (MERIT)Oct 23, 2026NCT07892651
Studies
Recruiting first, then most recently updated. Showing 50 of 144. Browse all 144 → or search them.
- Nephrotic Syndrome Study NetworkRecruitingNCT012090002 countries
- NEPTUNE Match StudyRecruitingNCT04571658Not applicable1 country
- A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN)RecruitingNCT06962800Phase 311 countries
- An Open-Label Phase 2 Study of N-Acetyl-D-Mannosamine (ManNAc) in Subjects With Podocyte DiseasesRecruitingNCT06664814Phase 21 country
- Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)RecruitingNCT07204275Phase 2/314 countries
- Rituximab Plus Cyclosporine in Idiopathic Membranous NephropathyRecruitingNCT00977977Phase 21 country
- MENA/Levant Epidemiological, Registry of Immunological & Clinical Traits (MERIT)Not yet recruitingNCT078926511 country
- Correlation and Clinical Utility of Urinary Biomarker in Membranous GlomerulonephritisRecruitingNCT056888651 country
- A Study to Assess the Effect of Surovatamig in Adult Participants With Antibody-mediated Kidney DiseaseRecruitingNCT07571746Phase 29 countries
- A Phase 2 Study of Budoprutug in Subjects With Primary Membranous NephropathyRecruitingNCT07096843Phase 27 countries
- Combination of Rituximab and Cyclosporine in the Treatment of Primary Membranous NephropathyRecruitingNCT07861204Phase 2/31 country
- A Phase 3 Study of Inebilizumab in Participants With Primary Membranous NephropathyRecruitingNCT07851220Phase 31 country
- A Phase I Study of YK012 in Primary Membranous NephropathyNot yet recruitingNCT07234474Phase 1
- Evaluation of the Efficacy of Zuberitamab Injection in Patients With Primary Membranous NephropathyNot yet recruitingNCT07830433Phase 31 country
- Belimumab With Rituximab for Primary Membranous NephropathyRecruitingNCT03949855Phase 21 country
- A Clinical Study Evaluating the Safety and Efficacy of GT719 Universal Cell Injection in the Treatment of Immune-mediated Kidney DiseasesNot yet recruitingNCT07389499Early Phase 11 country
- Single-cell RNA Sequencing (scRNA-seq) to Investigate the Mechanisms Underlying the Induction of Regulatory T Cells in Patients With Extramembranous Glomerulonephritis Treated With RituximabNot yet recruitingNCT07811557Not applicable1 country
- Clinical Prediction Model for Disease Progression in Primary Membranous NephropathyNot yet recruitingNCT07785739
- A Phase I/II Open-label, Single-arm, Multicenter Clinical Study to Evaluate the Safety and Efficacy of FKC289 in Subjects With Relapsed/Refractory Membranous NephropathyNot yet recruitingNCT07765537Phase 1/21 country
- Obinutuzumab for Systemic Lupus Erythematosus Pure Membranous Nephropathy: a Phase II TrialNot yet recruitingNCT07721363Phase 21 country
- Epithelial Dysmetabolism and Renal Fibrosis in ANCA VasculitisRecruitingNCT070102501 country
- Personalized Rituximab Treatment Based on Artificial Intelligence in Membranous Nephropathy (iRITUX)RecruitingNCT06341205Phase 31 country
- Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN)RecruitingNCT07157787Phase 210 countries
- Immunopathological Analysis in a French National Cohort of Membranous NephropathyRecruitingNCT04326218Not applicable1 country
- A Clinical Study of B007 in the Treatment of Primary Membranous Nephropathy.RecruitingNCT06470191Phase 2/31 country
- A Phase I Clinical Study of Recombinant Humanized Anti-CD20(B-lymphocyte Antigen CD20) Monoclonal Antibody Subcutaneous Injection in the Treatment of Primary Membranous NephropathyRecruitingNCT05668403Phase 11 country
- Efficacy and Safety of CD19 CAR-γδ T Cells in the Treatment of Relapsed/Refractory Autoimmune NephropathyNot yet recruitingNCT07535138Early Phase 11 country
- Efficacy and Safety of Finerenone in Patients With Primary Membranous NephropathyRecruitingNCT06573411Phase 41 country
- An Outcome Analysis of Primary Membranous NephropathyRecruitingNCT062423271 country
- Autoreactive B Cells in Membranous NephropathyRecruitingNCT040951561 country
- A Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Treatment With AP1189 in Patients With iMN and Severe ProteinuriaRecruitingNCT04456816Phase 21 country
- Clinical Study of Anti-CD19/BCMA Universal Chimeric Antigen Receptor T Cells (UCAR-T) in the Treatment of Refractory Idiopathic Membranous Nephropathy (IMN)Not yet recruitingNCT07423572Early Phase 11 country
- Omics of Rituximab-resistanceNot yet recruitingNCT074169421 country
- Rivaroxaban in Idiopathic Membranous NephropathyRecruitingNCT07404436Phase 41 country
- Phase II Randomized, Open-label, Multicenter Clinical Study Evaluating the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of SHR-2173 Injection in Patients With Primary Membranous NephropathyRecruitingNCT07289763Phase 21 country
- OBINOTUZUMAB Versus Cyclophosphamide + Glucocorticoids in Primary Membranous Nephropathy(Blossom Study)RecruitingNCT06781944Phase 31 country
- Obinutuzumab Induced Decreases of PLA2R Antibodies in Membranous Nephropathy: a Pilot StudyRecruitingNCT07163611Phase 2/31 country
- Safety and Efficacy of CD19 Chimeric Antigen Receptor T-Cell (CAR-T) in the Treatment of Refractory Membranous NephropathyRecruitingNCT07266181Phase 11 country
- Interview Study of Adult and Child Patients and Parents of Children With Swelling Due to Nephrotic Syndrome.RecruitingNCT055055001 country
- Different Immunosuppressive Treatment in iMNRecruitingNCT04745728Phase 31 country
- A Study to Evaluate the Efficacy, Safety, and Tolerability of Human Sialidase Fusion Protein (HLX79) in Combination With Rituximab Injection Versus Placebo in Patients With Active GlomerulonephritisRecruitingNCT07038382Phase 21 country
- Study of YK012 in Primary Membranous NephropathyRecruitingNCT06982729Phase 11 country
- A Real World Study About PMNRecruitingNCT068933281 country
- A Study to Learn More About the Effects and Safety of JMT601 in Adults With Primary Membranous NephropathyNot yet recruitingNCT07029139Phase 2
- Raman Spectroscopy Diagnosis of Kidney DiseasesRecruitingNCT067608451 country
- IM19 CAR-T Cell Therapy for IgA Nephropathy Patients and Membranous Nephropathy PatientsNot yet recruitingNCT06690359Early Phase 1
- The Efficacy and Safety of Treatment With Telitacicept in Primary Membranous NephropathyNot yet recruitingNCT06614985Phase 21 country
- Effect of Huaier Granule on the Treatment of Idiopathic Membranous NephropathyRecruitingNCT05839314Phase 41 country
- Rituximab, Cyclophosphamide, and Corticosteroids in Primary Membranous NephropathyRecruitingNCT05679336Not applicable1 country
- Clinical Study of Rituximab Combined With Corticosteroids or Rituximab Monotherapy in the Treatment of Primary Membranous NephropathyRecruitingNCT05514015Phase 41 country